A next-generation triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. This multi-pathway approach enhances satiety, boosts energy expenditure and fat oxidation through glucagon signaling, improves insulin sensitivity, and promotes significant lipolysis. It offers advanced metabolic benefits and superior weight loss potential beyond dual agonists.
